Compare Caesars Entertainment Inc (CZR) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Caesars Entertainment Inc vs IDEXX Laboratories, Inc. — how do they compare? Caesars Entertainment Inc trades at $29.49 (market cap $6.02B), while IDEXX Laboratories, Inc. trades at $516.73 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 6.7× Caesars Entertainment Inc's market cap, and Caesars Entertainment Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Caesars Entertainment Inc for 31 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| CZR | IDXX | |
|---|---|---|
Market Cap | $6.02B | $40.43B |
Volume | 6,412,151 | 692,164 |
Sector | Consumer Cyclical | Health |
52-Week High | $30.41 | $766.68 |
52-Week Low | $18.14 | $504.70 |
Typical Hold Time | 31 Days | 46 Days |
Enterprise Value | $29.91B | $41.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Caesars Entertainment (CZR) trades at $29.54, showing minimal daily movement with a 0.15% gain. The stock faces bearish technical signals and has missed earnings expectations for three consecutive quarters, with negative profitability metrics including -3.99% net income margin. The pending $31 per share acquisition by Fertitta Entertainment provides a potential floor, while recent news highlights shareholder investigations into the deal's fairness. Cash flow trends show improvement with net cash flow narrowing from -$689M in 2022 to -$32M in 2025.
CZR presents a mixed outlook with acquisition upside limited to 5% from current levels, offset by fundamental challenges including consistent earnings misses and negative margins. Key risks include merger uncertainty and high debt load, while analyst sentiment remains cautious with 68% hold ratings. The stock offers speculative appeal for merger arbitrage but lacks organic growth catalysts.
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Caesars Entertainment Inc
Caesars Entertainment includes around 50 domestic gaming properties across Las Vegas (50% of 2021 EBITDAR before corporate and digital expenses) and regional (63%) markets. Additionally, the company hosts managed properties and digital assets, the later of which produced material EBITDA losses in 2021. Caesars' U.S. presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973 and expanded its presence through prior acquisitions to over 20 properties before merging with legacy Caesars. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the U.S. portion of William Hill (it plans to sell the international operation in 2022), a digital sports betting platform.
Read more on CZR →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
